Western Wealth Management LLC Cuts Position in Merck & Co., Inc. (NYSE:MRK)

Western Wealth Management LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 73.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,677 shares of the company's stock after selling 21,044 shares during the period. Western Wealth Management LLC's holdings in Merck & Co., Inc. were worth $764,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Midwest Capital Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Financial Life Planners acquired a new position in Merck & Co., Inc. during the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new position in Merck & Co., Inc. during the fourth quarter worth $28,000. Halbert Hargrove Global Advisors LLC purchased a new stake in Merck & Co., Inc. during the fourth quarter worth $28,000. Finally, Promus Capital LLC purchased a new stake in Merck & Co., Inc. during the fourth quarter worth $30,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Insider Buying and Selling at Merck & Co., Inc.

In other news, SVP Dalton E. Smart III sold 4,262 shares of the company's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the transaction, the senior vice president now owns 7,778 shares of the company's stock, valued at $643,707.28. This represents a 35.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is owned by company insiders.

Merck & Co., Inc. Trading Down 0.3%

Shares of MRK opened at $77.59 on Friday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $134.63. The company has a market capitalization of $194.83 billion, a PE ratio of 11.53, a price-to-earnings-growth ratio of 0.77 and a beta of 0.43. The stock has a fifty day moving average of $81.76 and a two-hundred day moving average of $91.46. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating analysts' consensus estimates of $2.16 by $0.06. The business had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.07 earnings per share. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Bank of America dropped their price target on Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating for the company in a research report on Wednesday, February 5th. Morgan Stanley dropped their target price on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their target price for the stock from $128.00 to $105.00 in a research report on Tuesday, February 18th. Guggenheim reaffirmed a "buy" rating and issued a $115.00 price target on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Finally, Cantor Fitzgerald cut shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus price target of $109.19.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.